Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GelTex, Sankyo Pharma Inc. deal

The companies signed a letter of intent to grant Sankyo exclusive U.S. marketing rights for Cholestagel

Read the full 163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE